TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01554202

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: assessment of memory

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: assessment of memory

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: assessment of memory

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: assessment of memory

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: assessment of memory

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: assessment of memory

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: assessment of memory

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: assessment of memory

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: assessment of memory

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: circulating tPA dosage

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: circulating tPA dosage

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: circulating tPA dosage

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: circulating tPA dosage

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: circulating tPA dosage

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: circulating tPA dosage

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: circulating tPA dosage
Study: NCT03579654

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Proscavax
Description: Proscavax is a prostate cancer vaccine which combines the prostate antigen PSA with immune stimulatory cytokines (IL-2 and GM-CSF).
Study: NCT00291733

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levetiracetam
Description: 500mg (2 tabl of 250) for one week and 1000mg (4 tabl of 250) for one week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levetiracetam
Description: 500mg (2 tabl of 250) for one week and 1000mg (4 tabl of 250) for one week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tabl

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tabl
Study: NCT00349271

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem cell
Description: Stem cell

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastime (G-CSF)
Description: Filgrastime (G-CSF)
Study: NCT01600963

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Arm B Double-blind Phase: Placebo
Description: Form=tablet, route=oral administration, taken once daily for 2 weeks then 3 times per week for the remainder of the treatment period.
Study: NCT00349271

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standart therapy
Description: All drug with clinical evidence of benefical effect in Chagas disease
Study: NCT04955860

Intervention type: OTHER
Intervention: Dental model analysis
Description: No interventional treatment intervention will be made for individuals. Digital dental models taken for orthodontic recording will be examined.

Intervention type: OTHER
Intervention: Dental model analysis
Description: No interventional treatment intervention will be made for individuals. Digital dental models taken for orthodontic recording will be examined.
Study: NCT04219462

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active extracorporeal shock wave
Description: Ultrasound gel was used as a coupling agent, and the applicator of extracorpral shock wave therapy (ESWT) will be held perpendicular to the treatment surface throughout the treatment. Men in this group (n= 20) men receive ESWT twice weekly for 3 consecutive weeks and repeated after a 3-week rest period, for a total of 12 treatment sessions. The patients will receive ESWT for 15 minutes at an energy level of 0.09 and a frequency of 120 shocks/min (1800 pulses per session). Shockwaves were delivered to the distal, mid, and proximal penile shaft, as well as to the left and right crura + 5 mg sildnafil once daily for 3 months

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham extracorporeal shock wave
Description: twenty men will receive sham treatment underwent identical therapy with ESWT application with a similar appearance and sound as the active extracorporal shock wave therapy (ESWT), although shock wave propagation to the tissue wills be blocked by a metal plate that will inserted into the sham applicator + sildenafil 5mg once daily for 3 months.
Study: NCT02721979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT02347696

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control
Description: Subjects will follow a diet based on INRAN guidelines without doing any physical activity.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: LGIMD
Description: Subjects will follow a Low Glycemic Index Mediterranean Diet (LGIMD) without doing any physical activity.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Endurance Activity (EA)
Description: Subject will follow a program of endurance activity as follows:~Frequency: 3 times/week Duration: 60 minutes~Intensity:~* weeks 1-4: 14.2 kcal\*kg-1\*week-1;~* weeks 5-8: 18.9 kcal\*kg-1\*week-1;~* weeks 9-12: 23.6 kcal\*kg-1\*week-1.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: EA+Resistance Training (RT)
Description: Subject will follow a program of endurance activity as follows:~Frequency: 3 times/week Duration: 60 minutes~Intensity (for Endurance activity):~* weeks 1-4: 14.2 kcal\*kg-1\*week-1;~* weeks 5-8: 18.9 kcal\*kg-1\*week-1;~* weeks 9-12: 23.6 kcal\*kg-1\*week-1.~Resistance activity:~Muscolation: Training of the bigger muscle groups (chest, shoulders, arms, abdomen, back, glutes and legs);~* Progression: increase of 1-2.5 kg\*week-1~* Training of all muscle groups in the same session

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: LGIMD+EA
Description: Subjects will follow a Low Glycemic Index Mediterranean Diet together with a program of endurance activity.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: LGIMD+EA/RT
Description: Subjects will follow a Low Glycemic Index Mediterranean Diet together with a program of both endurance activity and resistance training.
Study: NCT02902679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986177
Study: NCT01440790

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: glucose bolus
Description: 50g anhydrous glucose dissolved in 300ml water consumed within 10min followed by a lunch (cheese sandwich, fruit and milk) at 4h.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucose sipping
Description: 50g anhydrous glucose dissolved in 300ml water consumed at rate of 25ml per 15min followed by a lunch (cheese sandwich, fruit and milk) at 4h.
Study: NCT01600963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment Failure During Double-blind Phase: TMC207
Description: Type=exact number, unit=mg, number=200 mg 3 times per week, form=tablet, route=oral administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Treatment Failure During Double-blind Phase: TMC207
Description: Type=exact number, unit=mg, number=200 mg 3 times per week, form=tablet, route=oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment Failure During Follow-up Phase: TMC207
Description: Type=exact number, unit=mg, number=400 mg once daily for 2 wks and 200mg three times per week for 22 weeks, form=tablet, route=oral administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Treatment Failure During Follow-up Phase: TMC207
Description: Type=exact number, unit=mg, number=400 mg once daily for 2 wks and 200mg three times per week for 22 weeks, form=tablet, route=oral administration.
Study: NCT03018925

Intervention type: DRUG
Intervention: Golimumab
Description: The treatment followed was an induction of 200 mg of Golimumab at week 0, and 100 mg at week 2. Under 70 Kg, the follow-up treatment dose would be 50 mg/month, and 100 mg/month in patients above 70 Kg asindicated in standard clinical practice.
Study: NCT01440790

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glucose bolus plus 1g vitamin C
Description: 50g anhydrous glucose dissolved in 300ml water consumed within 10min with 1g vitamin C followed by a lunch (cheese sandwich, fruit and milk) at 4h.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucose sipping plus 1g vitamin C
Description: 50g anhydrous glucose dissolved in 300ml water consumed at rate of 25ml per 15min. 1g vitamin C taken with first 25ml. Followed by a lunch (cheese sandwich, fruit and milk) at 4h.
Study: NCT01726660

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IMT Robotic Arm therapy
Description: Interactive Motion Technologies (IMT) planar and wrist robots for robotic arm therapy
Study: NCT02854215

Intervention type: OTHER
Group type: OTHER
Intervention: Collection of additional data with questionnaires
Description: * questionnaires for quality of life measurements: QLQC30; QLQ-OV28~* questionnaires for medico-economic purposes: ADL (activities of daily living); IADL (instrumental activities of daily living); EQ-5D3L; absenteeism questionnaire.~These questionnaires will be completed during the study time (5 or 6 times during the treatment, next every 4 months during the first two years and then every 6 months during the third year of follow-up).
Study: NCT01282476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat with Rituximab
Description: Panobinostat 40 mg orally 3 x weekly Rituximab 375 mg/m\^2 IV days 1,8,15,and 22 of cycle 1, and then on day 1 of subsequent cycles.
Study: NCT01783093

Intervention type: OTHER
Intervention: Data Collection
Description: Collection of data from existing medical records
Study: NCT01564082

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ETT First (GlideScope)
Description: Patients will have the endotracheal tube (ETT) introduced into the pharynx under direct vision prior to GlideScope insertion. The ETT will then be advanced under GlideScope guidance into the trachea.
Study: NCT05924490

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Real-time strategy-based videogame training
Description: Rise of Nation is a complex strategy-based video game, in which individualized-adaptive feedbacks are constantly given to players based on their performance.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Semantic Knowledge training
Description: Packages of various cross-word puzzles include word search, word ladder, and word wheel.
Study: NCT02209636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate
Description: Non-calcium containing phosphorus binder
Study: NCT01554202

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: circulating tPA dosage

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: circulating tPA dosage

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ApoE4
Study: NCT00655356

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1. Collection of 3 mm post auricular skin punch biopsies.~2. Three treatment visits with injections administered 5 ± 1 weeks apart on each side of the face.
Study: NCT01554202

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ApoE4

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ApoE4
Study: NCT01446510

Intervention type: OTHER
Intervention: Application of VTE Risk Assessment
Description: Use of a method to assess a patient's risk of VTE, and then appropriate prophylaxis for the assigned level of risk
Study: NCT02225782

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alteplase
Description: Alteplase is a fibrinolytic drug widely used to restore hemodialysis catheter patency.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alteplase
Description: Alteplase is a fibrinolytic drug widely used to restore hemodialysis catheter patency.
Study: NCT00087529

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Intravenous repeating dose
Study: NCT04129333

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: The hypnosis session :~* Creation of the therapist-patient link~* Choice of a theme and the preferred sensory channel by the patient~* Collection of the theme chosen by the patient~* Orientation in the here and now.~* Induction~* Realization of the gesture and hypnosis~* At the end of the procedure, reassociation of the patient in the here and now

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No hypnosis
Description: No hypnosis
Study: NCT01726660

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IMT Robotic Arm therapy
Description: Interactive Motion Technologies (IMT) planar and wrist robots for robotic arm therapy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IMT Robotic Arm therapy
Description: Interactive Motion Technologies (IMT) planar and wrist robots for robotic arm therapy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IMT Robotic Arm therapy
Description: Interactive Motion Technologies (IMT) planar and wrist robots for robotic arm therapy
Study: NCT04047927

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EpiFinder
Description: The EpiFinder is a sensing device intended to assist physicians performing placement of epidural needle analgesic and/or anesthesia injection in a safely and accurately manner. The device is a single use sterile device consisting of a probe (Stylet), an actuator (micro DC motor), IR sensor and Controller. The device is integrated to a standard LOR Syringe and an 18G Tuohy needle and enables to simultaneously work with the standard LOR technique.
Study: NCT01554202

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ApoE4

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ApoE4

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ApoE4

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ApoE4

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ApoE4

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ApoE4

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brain imaging examination MRI and PET examinations

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brain imaging examination MRI and PET examinations

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brain imaging examination MRI and PET examinations

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brain imaging examination MRI and PET examinations

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brain imaging examination MRI and PET examinations
Study: NCT02231047

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 64N Nutraceutical
Description: 40 mg/kg/day of powdered 64N mixed in 12 ounces of a warm drink for 1 week (7 days)

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: No 64N Nutraceutical
Description: 12 ounce warm drink daily for 1 week (7 days)
Study: NCT03109847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride
Description: Given Orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radioactive Iodine
Description: Undergo radioactive iodine treatment

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Radioactive Iodine
Description: Undergo radioactive iodine treatment
Study: NCT01554202

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brain imaging examination MRI and PET examinations

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brain imaging examination MRI and PET examinations
Study: NCT03109847

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given orally
Study: NCT03239561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]MNI-1020
Description: Participants will receive a single intravenous bolus injection of \[18F\]MNI-1020 at a dose of not more than 10 millicurie (mCi), with a maximum mass dose of 10 microgram (mcg) and maximum volume of 10 milliliter (mL) at imaging visit.
Study: NCT04146532

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 500 MG
Description: Single 500mg aspirin capsule.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single 500mg placebo capsule.
Study: NCT01498510

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based CBT for chronic pain
Description: An interactive, web-based intervention, based on principles of cognitive behavior therapy (CBT), that is designed to train chronic pain patients in self-management skills to reduce pain and aberrant behavior and improve functioning
Study: NCT02165852

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Papillectomy without injection
Description: Conventional endoscopic mucosal resection of ampulla of Vater using a snare with electrocurrent.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Papillectomy with injection
Description: Conventional endoscopic mucosal resection of ampulla of Vater without submucosal saline or diluted epinephrine injection.
Study: NCT04243369

Intervention type: DEVICE
Group type: OTHER
Intervention: Non-diagnostic software solution
Description: Collaboration Live is a non-diagnostic software solution intended for use with Philips (Philips Ultrasound, 22100 Bothell Everett Highway, Bothell, Washington 98021) EPIQ and Affiniti Series Ultrasound Systems (software version 5.0.2) that allows users to communicate (by text, voice, screen share, webcam video and remote takeover) from an ultrasound system or workstation to a remote destination.
Study: NCT00534846

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: toremifene
Description: The medication is given in tablet form, and the participants are instructed to take one tablet daily from cycle day 15 until the next menstruation. The active (toremifene 20 mg) and control (placebo) tablets were identical in appearance.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: tablet equal to toremifene, one tablet daily from cycle day 15 to menstruation during three cycles
Study: NCT04084639

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mycoprotein Ingestion
Description: Ingestion of various doses of mycoprotein compared to placebo control
Study: NCT03321812

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: decalcification bone scaffold
Description: Decalcification bone scaffold is a tissue engineering acellular matrix scaffold with the closest biomechanics and structure of normal cartilage.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: microfracture
Description: Microfracture is the surgical option for conventional treatment of cartilage defects.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: microfracture
Description: Microfracture is the surgical option for conventional treatment of cartilage defects.
Study: NCT01300143

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TACE
Description: Control arm will be treated by 2 or 3 cures of TACE DC beads at week 0, 8 and 16 (if required)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TACE+ RTC
Description: Experimental group will be treated by one cure of TACE DC Beads at week 0 then, within two weeks, by external conformational radiotherapy in 18 sessions
Study: NCT02734732

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trimethoprim/Sulfamethoxazole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin
Study: NCT02734550

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Patients are treated according to the ESCMID guidelines. Antifungal therapy is started if fungi are detected in the blood culture or other primary sterile body fluids.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Patients are treated according to the ESCMID guidelines. Antifungal therapy is started if fungi are detected in the blood culture or other primary sterile body fluids.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: (1,3)-β-D-glucan guided therapy
Description: Serum for (1,3)-β-D-glucan measurement is obtained after enrollment and 24 hours later. Antifungal therapy is started if at least one sample is 80 pg/ml or higher. If concomitantly taken microbiological cultures remain negative, antifungal therapy is continued only, if both (1,3)-β-D-glucan were at least 80 pg/ml. Blood cultures or other samples from primary sterile body fluids positive for fungi are treated with antifungals irrespective the (1,3)-β-D-glucan results.
Study: NCT03178461

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Body temperature parenteral fluids
Description: 2 study groups shall receive the same parenteral fluids but at different temperatures.
Study: NCT00108810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal Ketoprofen Patch with CHADD
Description: 12 hours patch application for 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo transdermal patch
Description: 12 hours application for 28 days
Study: NCT01396525

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Omnilink Elite™ Peripheral Balloon-Expandable Stent System
Description: Patients with treatment of a maximum of two bilateral de novo or restenotic atherosclerotic lesions in the native common iliac artery and/or native external iliac artery (one lesion per side).
Study: NCT01398254

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Primary Percutaneous Coronary Intervention (PPCI)
Description: Participants will be randomly assigned an access site, radial or femoral, for PPCI.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Primary Percutaneous Coronary Intervention (PPCI)
Description: Participants will be randomly assigned an access site, radial or femoral, for PPCI.
Study: NCT02642861

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclobenzaprine
Description: cyclobenzaprine administration for 2 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Calcium Carbonate
Description: Calcium carbonate for 2 weeks